RxDoctor Payments Data

Linda Summers, PA

Physician Assistant · Williamsburg, VANPI 1528202033

Payments from drug & device makers

$2,731in general payments, 2019–2025

Across 32 payments — averaging $85.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$332
  • Boston Scientific$208
  • E.r. Squibb & Sons, L.L.C.$124
  • Philips North America LLC$36
  • Novartis$23
  • plus $172 from 10 others

What the payments were for

  • Consulting fees$171%
  • Travel & lodging$1,15042%
  • Food & beverage$1,56457%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,731 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$63,166
Medicare patients
565
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$183,981
EntrestoSacubitril/Valsartan90$95,687
XareltoRivaroxaban47$49,830
JardianceEmpagliflozin28$40,833
FarxigaDapagliflozin Propanediol41$39,262
Repatha SureclickEvolocumab20$12,956
Metoprolol Succinate379$4,227
Diltiazem 24hr Er (Cd)Diltiazem Hcl81$3,993
Ranolazine ErRanolazine17$1,744
Valsartan43$1,665
Candesartan Cilexetil11$1,375
Atorvastatin Calcium125$1,374
Nifedipine ErNifedipine25$1,293
Isosorbide Mononitrate ErIsosorbide Mononitrate71$995
Digoxin55$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$23$95,68790 claims
Johnson & JohnsonXarelto$15$49,83047 claims
Boehringer IngelheimJardiance$16$40,83328 claims
AstraZenecaFarxiga$21$39,26241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →